Abstract：Objective The Chinese Children's Leukemia Group (CCLG)-acute lymphoblastic leukemia (ALL) 08 protocol for childhood ALL was established in 2008. This study aims to evaluate the drug-related toxicities of CCLG-ALL 08 protocol in the treatment of childhood ALL. Methods A total of 114 children with newly diagnosed ALL were treated with the CCLG-ALL 08 protocol. The protocol was divided into five phases: remission induction (VDLD), early reinforcement (CAM), consolidation therapy, delayed reinforcement (DIa & DIb) and maintenance treatment. Drug-related toxicities in each phase were evaluated according to the Common Terminology Criteria for Adverse Events version 4.0. Results Toxicities were more frequent in phase VDLD than other treatment phases, including hepatotoxicity (87.7%), dental ulcer (20.2%), hyperglycemia (20.2%), prolonged activated partial thromboplastin time (21.1%) and decreased fibrinogen (34.2%), with the incidence rates of severe adverse events at 7%, 0, 1.3%, 0.8% and 2.7% respectively. The incidence of allergic reaction to L-ASP was significantly higher in phase DIa than in phase VDLD (28.0% vs 7.9%; P<0.01), and there were no longer any allergic reactions in 15 patients who received continuing treatment with pegaspargase instead. There was no severe arrhythmia, myocardial ischemia, decreased left ventricular function, osteonecrosis, myopathy, organ failure or treatment-related mortality. Conclusions The drug-related toxicities of CCLG-ALL 08 protocol are common in phase VDLD, but they are mild and reversible. There is no treatment-related mortality. The CCLG-ALL 08 protocol for childhood ALL is safe.
CHEN Bo,XIAN Ying,SU Yong-Chun et al. A clinical study of drug-related toxicities of CCLG-ALL 08 protocol for childhood acute lymphoblastic leukemia[J]. CJCP, 2013, 15(9): 737-742.
National Institutes of Health; National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE).Version 4.0[S]. 2009.
[3]
金晟娴. 04方案治疗儿童急性淋巴细胞白血病毒副作用临床研究[D].重庆医科大学,2010.
[4]
Grattagliano I, Bonfrate L, Diogo CV, Wang HH, Wang DQ, Portincasa P. Biochemical mechanisms in drug-induced liver injury: certainties and doubts[J]. World J Gastroenterol, 2009, 15(39): 4865-4876.
[5]
Bowman WP, Larsen EL, Devidas M, Linda SB, Blach L, Carroll AJ, et al. Augmented Therapy improves Outcome for Pediatric High Risk Acute Lymphocytic leukemia: Results Of Children's Oncology Group Trial P9906[J]. Pediatr Blood Cancer, 2011, 57(4): 569-577.
[6]
Albayrak M, Gürsel T, Kaya Z, Kocak U.Alterations in procoagulant, anticoagulant, and fibrinolytic systems before and after start of induction chemotherapy in children with acute lymphoblastic leukemia[J/OL]. Clin Appl Thromb Hemost (
[7]
Hunault-Berger M, Chevallier P, Delain M, Bulabois CE, Bologna S, Bernard M, et al. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study[J]. Haematologica, 2008, 93(10): 1488-1494.
[8]
Childhood Acute Lymphoblastic Leukaemia Collaborative Group (CALLCG). Beneficial and harmful effects of anthracyclines in the treatment of childhood acute lymphoblastic leukaemia:a systematic review and meta-analysis[J]. Br J Haematol, 2009, 145 (3): 376-388.
[9]
Fulbright JM, Huh W, Anderson P, Chandra J. Can anthracycline therapy for pediatric malignancies be less cardiotoxic[J]. Curr Oncol Rep, 2010, 12(6): 411-419.
Teuffel O, Kuster SP, Hunger SP, Conter V, Hitzler J, Ethier MC, et al. Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis[J]. Leukemia, 2011, 25(8): 1232-1238.
[12]
Kadan-Lottick NS, Brouwers P, Breiger D, Kaleita T, Dziura J, Liu H, et al. A comparison of neurocognitive functioning inchildren previously randomized to dexamethasone or prednisone in the treatment of childhood acute lymphoblastic leukemia[J]. Blood, 2009, 114(9): 1746-1752.
[13]
Mitchell CD, Richards SM, Kinsey SE, Lilleyman J, Vora A, Eden TO, et al. Benefit of dexamethasone compared with prednisolone for childhood acutr lymphoblastic leukemia:results of UK Medical Research Council ALL 97 randomizde trial[J]. Br J Haematol, 2005, 129(6): 734-745.
[14]
McNeer JL, Nachman JB. The optimal use of steroids in paediatric acute lymphoblastic leukemia: no easy answers[J].British J Haematol, 2010, 149(5): 638-652.
[15]
Mattano LA Jr, Devidas M, Nachman JB, Sather HN, Hunger SP, Steinherz PG, et al. Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial[J]. Lancet Oncol, 2012, 13(9): 906-915.
